The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study
Main finding · Overall reduction of HOMA2-IRResult — go to the resultβ - 1.1 95% CI - 1.5 to - 0.76Authors' conclusion
The administration of tofacitinib in RA with T2D led to a simultaneous improvement of IR and inflammatory disease activity, inducing a "bidirectional" benefit in these patients.
Study context
- Population
- Consecutive rheumatoid arthritis (RA) patients with T2D diagnosisfemale sex 68.9%
- Participants
- 40 patients
- Outcome
- Change in homeostatic model assessment of IR (HOMA2-IR)
- Follow-up
- 6 months
Methodological detailsproof-of-concept, open, consecutive patients, Planned before the recent emergence of safety signals about tofacitinib
- Proof-of-concept
- Open
- Consecutive patients
- Planned before the recent emergence of safety signals about tofacitinib
Main finding
Overall reduction of HOMA2-IR
β
- 1.1
95% CI - 1.5 to - 0.76
P = 0.019
As reported in the abstract
Observational data: associations, not effects.
Further findings
HOMA2-β
- HOMA2-β enhanced, highlighting an improvement of insulin sensitivity
Glycated haemoglobin
- Trend in glycated haemoglobin reduction
- A longer follow-up is required
RA disease activity
- Patients achieving a good clinical response
- 76.8%
- Significant reduction of DAS28-CRP and SDAI
Safety
- No major adverse events (AEs), no life-threatening AEs and no cardiovascular and/or thromboembolic events recorded; no new safety signals
Original publication
The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study. Arthritis Res Ther. Published 4 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →